Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Deregulation of angiopoietin-like 4 slows ovarian cancer progression through vascular endothelial growth factor receptor 2 phosphorylation

Fig. 5

Analysis of the VEGFR2/VE-cadherin/Src complex in A2780 and CAOV3 tumors treated with or without siRNA targeting ANGPTL4. a Immunoprecipitation (IP) of vascular endothelial growth factor receptor 2 (VEGFR2) and immunoblotting (IB) of VE-cadherin, Src kinase phosphorylated at tyrosine 416 (Src pY416), Src, and VEGFR2. Total lysates were immunoblotted for VEGFR2 phosphorylated at tyrosine 949 (VEGFR2 pY949), VEGFR2, VE-cadherin, Src pY416, Src, and GAPDH; n = 3 independent experiments per group. b VE-cadherin/VEGFR2 ratio in immunoprecipitates from A2780 and CAOV3 tumors. c The Src pY416 level normalized to that of GAPDH or Src and the Src/GAPDH ratio were determined in immunoblots of A2780 and CAOV3 total lysates. d The VEGFR2 pY949 level normalized to that of GAPDH or VEGFR2 and the VEGFR2/GAPDH ratio were analyzed in total lysates by immunoblotting. e VE-cadherin/GAPDH ratio in immunoblots of A2780 and CAOV3 total lysates. **p < 0.01, ***p < 0.001 for the indicated comparisons. ns indicates no significance. The data are presented as the mean ± SEM values

Back to article page